- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06281665
Tratamiento con aspirina después de la preeclampsia: ensayo TAP (TAP)
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Alisse K Hauspurg, MD
- Número de teléfono: 412-641-1381
- Correo electrónico: janickia@upmc.edu
Copia de seguridad de contactos de estudio
- Nombre: Sila Yavan, MS
- Número de teléfono: 4124174981
- Correo electrónico: yavans@upmc.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Reclutamiento
- University of Pittsburgh Magee-Womens Hospital
-
Contacto:
- Sila Yavan, MS
- Número de teléfono: 4124174981
- Correo electrónico: yavans@upmc.edu
-
Investigador principal:
- Alisse K Hauspurg, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Postpartum individuals ≥18 years old
- Preeclampsia diagnosis
Exclusion Criteria:
- Fetal anomaly
- Multiple gestation
- Pre-pregnancy hypertension
- Allergy or contraindication to low-dose aspirin
- Pre-pregnancy diabetes
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo Group
Similar appearing placebo pill daily for 6 months will be given to subjects. |
The control group will receive similar appearing placebo daily for 6 months. |
|
Experimental: Intervention Group
Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects |
The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percent of participants eligible, enrolled and retained (feasibility)
Periodo de tiempo: Baseline to approximately 6 months postpartum
|
To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia. |
Baseline to approximately 6 months postpartum
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Study visit systolic BP
Periodo de tiempo: 2 months postpartum
|
Mean study visit systolic BP |
2 months postpartum
|
|
Study visit diastolic BP
Periodo de tiempo: 2 months postpartum
|
Mean study visit diastolic BP |
2 months postpartum
|
|
Study visit systolic BP
Periodo de tiempo: 6 months postpartum
|
Mean study visit systolic BP |
6 months postpartum
|
|
Study visit diastolic BP
Periodo de tiempo: 6 months postpartum
|
Mean study visit diastolic BP |
6 months postpartum
|
|
Study visit mean arterial pressure
Periodo de tiempo: 2 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
2 months postpartum
|
|
Study visit mean arterial pressure
Periodo de tiempo: 6 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
6 months postpartum
|
|
Anti-hypertensive medication use
Periodo de tiempo: 2 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
2 months postpartum
|
|
Anti-hypertensive medication use
Periodo de tiempo: 6 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
6 months postpartum
|
|
Therapeutic intensity score
Periodo de tiempo: 2 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
2 months postpartum
|
|
Therapeutic intensity score
Periodo de tiempo: 6 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
6 months postpartum
|
|
Mean home systolic blood pressure
Periodo de tiempo: delivery through 6 months postpartum
|
Mean home systolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home diastolic blood pressure
Periodo de tiempo: delivery through 6 months postpartum
|
Mean home diastolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home mean arterial pressure
Periodo de tiempo: delivery through 6 months postpartum
|
Mean home mean arterial pressure |
delivery through 6 months postpartum
|
|
Mean daytime systolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean daytime systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal systolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime diastolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal diastolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal mean arterial pressure
Periodo de tiempo: 6 months postpartum
|
Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime mean arterial pressure
Periodo de tiempo: 6 months postpartum
|
Mean daytime mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall mean arterial pressure
Periodo de tiempo: 6 months postpartum
|
Mean overall mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall systolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean overall systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall diastolic blood pressure
Periodo de tiempo: 6 months postpartum
|
Mean overall diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Classification of hypertension
Periodo de tiempo: 2 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
2 months postpartum
|
|
Classification of hypertension
Periodo de tiempo: 6 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
6 months postpartum
|
|
Endothelial function EC50%
Periodo de tiempo: 2 months postpartum
|
EC50% from microiontophoresis |
2 months postpartum
|
|
Endothelial function EC50%
Periodo de tiempo: 6 months postpartum
|
EC50% from microiontophoresis |
6 months postpartum
|
|
Endothelial function Emax
Periodo de tiempo: 2 months postpartum
|
Emax from microiontophoresis |
2 months postpartum
|
|
Endothelial function Emax
Periodo de tiempo: 6 months postpartum
|
Emax from microiontophoresis |
6 months postpartum
|
|
Endothelial function change in Emax
Periodo de tiempo: 2 to 6 months postpartum
|
Change in Emax between visits |
2 to 6 months postpartum
|
|
Endothelial function change in EC50%
Periodo de tiempo: 2 to 6 months postpartum
|
Change in EC50% between visits |
2 to 6 months postpartum
|
|
Change in systolic blood pressure
Periodo de tiempo: 2 to 6 months postpartum
|
Change in study visit mean systolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in diastolic blood pressure
Periodo de tiempo: 2 to 6 months postpartum
|
Change in study visit mean diastolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in mean arterial pressure
Periodo de tiempo: 2 to 6 months postpartum
|
Change in study visit mean arterial pressure between visits |
2 to 6 months postpartum
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Infecciones
- Eclampsia
- Preeclampsia
- Hipertensión, inducida por el embarazo
- Hipertensión
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Complicaciones del embarazo
- Toxemia
- Químicos orgánicos
- Hidrocarburos
- Hidrocarburos, cíclico
- Hidrocarburos, aromáticos
- Fenoles
- Derivados de benceno
- Salicilatos
- Hidroxibenzoates
- Aspirina
Otros números de identificación del estudio
- STUDY23080099
- K23HL168356 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.
Marco de tiempo para compartir IPD
Within a year after outcomes are published and no later than 3 years after the end of clinical activities.
Criterios de acceso compartido de IPD
NHLBI data repository request process
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .